Core Viewpoint - The company has approved a licensing and commercialization agreement for BAT2206, receiving a milestone payment of $2.5 million from Jireh Pharmaceuticals, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The company received a one-time milestone payment of $2.5 million, which strengthens its cash reserves [1] - The payment is expected to assist in the advancement of the company's pipeline research and international strategy [1] Group 2: Product Development - BAT2206 injection has been approved for market by the U.S. FDA and the European Medicines Agency, with the U.S. brand name STARJEMZA® and the European brand name Usymro® [1] - The company has submitted a marketing application to the National Medical Products Administration, which is currently under review [1]